首页> 美国卫生研究院文献>Infection Chemotherapy >Diagnostic Usefulness of Cytomegalovirus (CMV)-Specific T Cell Immunity in Predicting CMV Infection after Kidney Transplantation: A Pilot Proof-of-Concept Study
【2h】

Diagnostic Usefulness of Cytomegalovirus (CMV)-Specific T Cell Immunity in Predicting CMV Infection after Kidney Transplantation: A Pilot Proof-of-Concept Study

机译:巨细胞病毒(CMV)特异性T细胞免疫在预测肾脏移植后CMV感染中的诊断有用性:概念验证性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundCytomegalovirus (CMV) is one of the most important opportunistic infections in transplant recipients. Currently sero-positivity for CMV IgG before solid organ transplantation is the laboratory test of choice for stratifying the risk of CMV reactivation after solid organ transplantation. Theoretically, CMV-specific cell-mediated immune responses before solid organ transplantation should further categorize patients as high or low risk of CMV development. We therefore evaluated the usefulness of the CMV-specific enzyme-linked immunospot (ELISPOT) assay in kidney transplant (KT) candidates for predicting the development of CMV infections after transplantation.
机译:背景巨细胞病毒(CMV)是移植受体中最重要的机会感染之一。目前,实体器官移植前对CMV IgG的血清阳性是选择用于分层实体器官移植后CMV重新激活风险的实验室测试。从理论上讲,在实体器官移植之前,CMV特异性细胞介导的免疫反应应进一步将患者分类为CMV发生的高风险或低风险。因此,我们评估了CMV特异性酶联免疫斑点(ELISPOT)检测在肾移植(KT)候选物中用于预测移植后CMV感染发展的有用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号